Maj bank Image empty

Protai Bio

Protai Bio utilizes an AI-powered platform to map the progression of diseases at the protein level and discover new drugs. Protai is one of the leading companies in predicting the behavior of protein networks under various conditions and how these networks respond when exposed to a drug. This approach is more cost-effective than traditional trial and error drug discovery methods.

Investment rationale

Best-in-class technological foundation combining proteomics and machine learning. A scalable business model predicated on an AI platform with limited marginal costs. Backed by a management team of leading researchers in oncology and proteomics. 

Headquarters: Tel-Aviv, Israel


Fund: MIM I


Year of investment


Maj bank Image empty